FDA's 510(k) database lists Radiopharmaceutical Imaging & Dosimetry, LLC as applicant for 3D-RD-S under K262060, received June 18, 2026 and decided September 4, 2026 as substantially equivalent, with product code LLZ and the radiology advisory committee. The company's own announcement, dated September 11, 2026, describes the clearance as covering 3D-RD-S together with optional imaging functionality called 3D-RD-Si. The same announcement identifies the applicant as Rapid and describes a Baltimore, Maryland company. FDA filing addresses are not treated here as a verified headquarters. [1][5]

The applicant and its documented product

The FDA record for K262060 names Radiopharmaceutical Imaging & Dosimetry, LLC as applicant, with device name 3D-RD-S, product code LLZ, regulation number 892.2050, device class 2 and medical specialty radiology. The decision is recorded as SESE, substantially equivalent, with a summary statement and a traditional clearance type. The same record lists a Baltimore, Maryland address and a contact name. [1]

The company's product page describes 3D-RD-S as its first SaaS product, a web-based application used to perform radiopharmaceutical dosimetry and to calculate an estimate of absorbed dose and related radiobiological quantities. The company's clearance announcement describes 3D-RD-S as including new optional imaging functionality, 3D-RD-Si, and frames the clearance as expanding the 3D-RD platform toward an integrated workflow covering image review, segmentation, quantification and MIRD S-value dosimetry in one web-based platform. [4][5]

Earlier clearance and stated technical scope

An earlier FDA clearance letter, K212587 dated February 22, 2023, names Radiopharmaceutical Imaging and Dosimetry, LLC and trade device 3D-RD-S under regulation 21 CFR 892.1100, product code IYX, regulatory class I reserved. That letter is a separate filing from K262060 and is cited only for its own contents. [6]

The company's announcement of that earlier clearance describes 3D-RD-S as a web-browser application implementing the MIRD Schema for radiopharmaceutical dosimetry calculations, based on ICRP phantoms and data, supporting 1,252 radionuclides and including features for alpha-emitter dosimetry and daughter radionuclide accounting. These are the company's published characterizations, not independently verified performance results. [7]

Services and published company description

The company's website describes services related to quantitative imaging and dosimetry in support of pre-clinical and clinical studies, alongside a growing suite of software products. Its about page states that the team draws on a combined 45+ years of NIH-funded research and describes products and services as expert dosimetry analysis accompanied by advice on regulatory requirements, imaging protocol design and organ toxicity. Those statements originate with the company. [3][9]

A federal SBIR award listing names Radiopharmaceutical Imaging and Dosimetry, LLC at the same Baltimore address for a cloud and subscription-based, customer-responsive dosimetry tool for alpha-particle emitters, and lists George Sgouros as a contact. The listing is cited only for the award record's own contents. [8]

What the filing record does and does not establish

The linked collection contains one 510(k) record, K262060, and the decision count for that collection is one SESE decision; the record sample likewise contains that single entry. These are counts of the linked filings as retrieved, not measures of company sales, total portfolio or safety performance. No recall records appear in the linked sample. [1]

The company's product page also references CE marking for 3D-RD-S in a press-release link, and a separate page invites readers to sign up for early access with a pre-launch discount code. Neither the FDA records nor the company pages reviewed establish commercial availability, customer identities, ownership structure or clinical outcomes, and those points remain unknown here. [4][9]